TJM Labs Leadership Team & Executives

Jonathan Adly

Founder & CEO

Jonathan Adly is the founder and CEO of TJM Labs, a pharmacy AI platform headquartered in the United States. Adly grew up in a family that pushed him toward medicine, and pharmacy became a compromise between his parents' wishes and his own ambitions. He earned a PharmD, completed a postdoctoral residency, and later pursued an MBA as he transitioned toward entrepreneurship. His early career included academic publishing and administrative roles within health systems, where he developed a deep understanding of pharmacy supply chains and government interventions affecting pharmacy economics. Before founding TJM Labs, Adly founded Galen AI, a B2B healthcare AI company built on a software stack similar to Open Evidence. Galen AI was bootstrapped, signed its first enterprise customer at a contract value in the range of $250,000 to over $1 million per year, and was acquired within approximately a year and a half of founding. The acquirer was Carrie RX, which Adly described as a great software company that valued Galen AI's early AI infrastructure. Adly then joined Carrie RX as head of AI infrastructure. Carrie RX itself was subsequently acquired approximately six months before the July 2026 interview. Adly described the Galen AI exit as a meaningful personal financial event, though specific revenue figures are under NDA. Adly founded TJM Labs in late 2024, writing the first line of code in November 2024 after a pharmacy customer needed to rapidly staff approximately 200 technicians in four weeks. The company officially launched to additional customers in February 2025 with $1 million in ARR, scaled to $15 million ARR by December 2025, and reached approximately $25 million ARR by mid-2026, serving 450 pharmacy logos. TJM Labs raised a $10 million Series A in December 2025, a $15 million Series A1 in March 2026, and a $75 million Series B from Elephant in June 2026 at greater than 15x ARR multiple, implying a valuation above $375 million. The company operates at 40% EBITDA margin and its bots process roughly 500,000 prescriptions per day.